This study investigated the relationship between peak stimulated growth hormone (GH) and
body mass index (BMI), as well as the impact of BMI on therapeutic response in patients with …

Objective The International Cooperative Growth Study, NutropinAq® European Registry
(iNCGS)(NCT00455728) monitored long-term safety and effectiveness of recombinant …

Objective: Polyethylene glycol recombinant human growth hormone (PEG-rhGH,
Jintrolong®) is the first long-acting rhGH preparation that is approved to treat children with …

Context Despite having normal growth hormone (GH) secretion, individuals with Turner
syndrome (TS) have short stature. Treatment with recombinant human GH is recommended …

Objectives Growth hormone (GH) therapy's capacity to increase height velocity and height at
the end of the study in children with idiopathic short stature (ISS) is controversial. We aimed …

Introduction: PATRO Children is an international, observational, postmarketing surveillance
study for a biosimilar recombinant human growth hormone (rhGH; somatropin, Omnitrope®; …

Purpose To explore the characteristics of growth disturbance in patients with intracranial
germinoma with different origins. Methods Clinical data of 151 patients with single-origin …

There are known geographical differences in growth hormone deficiency (GHD) patient
populations and treatment practices. Here, we present a comparison of safety and …

For the treatment of pituitary dwarfism (called pituitary short stature in 1987 and renamed as
growth hormone deficiency [GHD] in 1993), pituitary-derived human growth hormone …

Purpose To describe the data from the Greek cohort of the Genetics and
Neuroendocrinology of Short Stature International Study (GeNeSIS). Methods GeNeSIS was …